RAPT Therapeutics is offering the first look at Phase II data suggesting that adding its small molecule CCR4 antagonist to Keytruda is leading to hoped-for responses — even in patients who otherwise wouldn’t be expected to respond. And it’s now looking for a partner to help take the program forward.
